Prevalence of current tobacco use, females in Europe & Central Asia
Europe & Central Asia: Prevalence of current tobacco use, females was 18.7% in 2024. ▼ Falling
Prevalence of current tobacco use, females in Europe & Central Asia, 2000–2024
Source: Global Health Observatory Data Repository, World Health Organization (WHO). Measured in % of female adults.
Analysis
In 2024, prevalence of current tobacco use, females in Europe & Central Asia stood at 18.7%. That is the lowest value across all 9 years on record.
Compared with earlier readings it is down 0.7% on the previous year and down 7.5% over ten years.
Over the whole period, prevalence of current tobacco use, females in Europe & Central Asia peaked at 24.5% in 2000 and was at its lowest, 18.7%, in 2024.
Europe & Central Asia ranks 4th of 46 groups on this measure, in the top 10%.
Prevalence of current tobacco use, females in Europe & Central Asia, year by year
| Year | % of female adults | Change |
|---|---|---|
| 2000 | 24.5% | — |
| 2005 | 22.8% | -6.9% |
| 2007 | 22.2% | -2.5% |
| 2010 | 21.4% | -3.8% |
| 2015 | 20.3% | -5.4% |
| 2020 | 19.3% | -4.6% |
| 2022 | 19.0% | -1.5% |
| 2023 | 18.9% | -0.8% |
| 2024 | 18.7% | -0.7% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 23.2% | 22.2% | 24.5% | 3 |
| 2010s | 20.8% | 20.3% | 21.4% | 2 |
| 2020s | 19.0% | 18.7% | 19.3% | 4 |
Countries ranked near Europe & Central Asia
More health data for Europe & Central Asia
- Population ages 45-49, female, annual growth rate 0.9265 % change on previous year (2025)
- Population ages 45-49, male, per capita 0.0339 units per person (2025)
- Population ages 45-49, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 10-14, female, per capita 0.0299 units per person (2025)
- Population ages 45-49, male, annual growth rate 1.04 % change on previous year (2025)
- Population ages 45-49, female, per capita 0.0346 units per person (2025)
- Population ages 45-49, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 10-14, male, annual growth rate 0.6344 % change on previous year (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, per capita 0.0352 units per person (2025)
Frequently asked questions
- What is prevalence of current tobacco use, females in Europe & Central Asia?
- Prevalence of current tobacco use, females in Europe & Central Asia was 18.7% in 2024, according to Global Health Observatory Data Repository, World Health Organization (WHO).
- What is the highest prevalence of current tobacco use, females recorded in Europe & Central Asia?
- The highest recorded value was 24.5% in 2000.
- What is the lowest prevalence of current tobacco use, females recorded in Europe & Central Asia?
- The lowest recorded value was 18.7% in 2024.
- How does Europe & Central Asia rank for prevalence of current tobacco use, females?
- Europe & Central Asia ranks 4th out of 46 groups with data for 2024.
- Is prevalence of current tobacco use, females rising or falling in Europe & Central Asia?
- Over the last ten years it is down 7.5%. The long-run trend across the full record is falling.
- Where does this Europe & Central Asia data come from?
- The figures come from Global Health Observatory Data Repository, World Health Organization (WHO), published as part of Prevalence of current tobacco use, females (% of female adults). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 9 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
The percentage of the female population ages 15 years and over who currently use any tobacco product (smoked and/or smokeless tobacco) on a daily or non-daily basis. Tobacco products include cigarettes, pipes, cigars, cigarillos, waterpipes (hookah, shisha), bidis, kretek, heated tobacco products, and all forms of smokeless (oral and nasal) tobacco. Tobacco products exclude e-cigarettes (which do not contain tobacco), “e-cigars”, “e-hookahs”, JUUL and “e-pipes”. The rates are age-standardized to the WHO Standard Population.